|Title:||R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them|
|Abstract:||R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.|
|Inventor(s):||Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL)|
|Assignee:||Teva Pharmaceutical Industries Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form; Formulation;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Israel||92952||Jan 03, 1990|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.